Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : InfoSpace (INSP): Where GNET went! -- Ignore unavailable to you. Want to Upgrade?

To: BillT who wrote (7810)	6/21/1999 2:48:00 PM
From: out_of_the_loop	Read Replies (1) \| Respond to of 28311

I called the reporter who wrote the story in the WSJ Interactive Journal and he told me he was aware of the Go2Net error and there would be a correction. He was very courteous and thanked me for the call. OT - The last time I called the WSJ to correct an error of theirs I did not get any response. About 6 weeks ago, the health section ran a story about a cold treatment called Tremacamra that is an experimental genetically manufactured ICAM receptor blocker that Boerhinger developed with the Medical University of South Carolina scientists. They called the drug a "vaccine" several times in their article and did not mention that it was not going to be produced. Being a major stockholder (at least for me) of GUMM, which has come out with Zicam (which works on that precise mechanism, as well as two others), I was majorly p--s-- off because NOBODY had called it a vaccine in the JAMA article to which the WSJ referred. I thought it was irresponsible of them and might lead to the uninformed selling of GUMM. Anyway, I left the EDITOR of that section a phone message (serendipity had it that she was home with a cold) AND I e-mailed the WSJ health writers directly. I got no response from either the e-mail or the phone call. They are going to look stupid (to anyone who remembers) when Zicam becomes the #1 treatment for colds (because it shortens the duration of the common cold from an average of 10-14 days to an average of 1.5 days) by the end of next cold season. So, I am somewhat sensitive to nonfactual material in the WSJ. I have TWO other stories about stocks that were reported about inaccurately in the WSJ but I am risking getting spammed for OT posts, so I will save them.